Composition and kit for detecting drug resistance gene of mycoplasma pneumoniae, and use thereof
Detecting the drug resistance sites of the 23S rRNA, 16S rRNA, gyrA and parC genes of Mycoplasma pneumoniae in a single tube reaction through multiplex PCR and nucleic acid mass spectrometry technology, solving the detection problems in the prior art and achieving rapid and accurate drug resistance genes Testing improves the accuracy and efficiency of treatment.
Patent Information
- Application Number
- PCT/CN2024/092048
- Authority / Receiving Office
- WO · WO
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2023-05-25
- Filing Date
- 2024-05-09
- Publication Date
- 2024-11-28
AI Technical Summary
The prior art is difficult to detect the drug resistance genes of Mycoplasma pneumonia quickly and accurately, resulting in frequent drug resistance problems during treatment, affecting the health of children and adolescents.
Using multiple PCR technology and nucleic acid mass spectrometry technology, the drug resistance sites on the 23S rRNA, 16S rRNA, gyrA and parC genes of Mycoplasma pneumoniae were detected simultaneously in a tube of reaction solution, and combined with a single base extension reaction to achieve early stage. Fast and accurate etiological diagnosis.
It realizes detection with low sample size, high sensitivity and high accuracy, and can detect eight targets simultaneously in a single tube of reaction, reducing the detection time and sample size and improving the accuracy of treatment.
Smart Images

Figure CN2024092048_28112024_PF_FP_ABST
Abstract
Description
Composition, kit and use thereof for detecting Mycoplasma pneumoniae drug-resistant genes
[0001] CROSS-REFERENCE TO RELATED APPLICATIONS
[0002] This application is based on the Chinese patent application with application number 202310601984.8 and application date May 25, 2023, and claims the priority of the Chinese patent application. The entire content of the Chinese patent application is hereby incorporated into this application by introduction. Technical Field
[0003] The present invention belongs to the field of molecular biological detection, specifically, to the detection of Mycoplasma pneumoniae resistance genes, and more specifically, to a composition, method and use for detecting resistance sites on 23S rRNA, 16S rRNA, gyrA and parC genes. Background Art
[0004] Mycoplasma pneumoniae (MP) infection can cause clinical diseases including upper respiratory tract infection, tracheobronchitis, and pneumonia. The highest incidence rate is among adolescents, especially those around school age who are more susceptible to M. pneumoniae. Severe Mycoplasma pneumonia in children often has an acute onset, severe illness, a long course, and multiple complications, seriously threatening children's life and health. M. pneumoniae infection accounts for 10% to 40% of community-acquired pneumonia in children. In recent years, many countries and regions have reported an increase in the infection rate and drug resistance rate of M. pneumoniae, seriously endangering the health of children and adolescents.
[0005] Expert consensus on the diagnosis and treatment of Mycoplasma pneumonia in children, released in some countries, lists macrolide antibiotics as the first choice for treating Mycoplasma pneumonia. However, the biggest challenge currently facing the treatment of Mycoplasma pneumonia in children is drug resistance.
[0006] Therefore, when choosing medication, clinicians often need to consider whether the patient is resistant to macrolides and other commonly used drugs.
[0007] Therefore, this field requires an early, rapid, and accurate etiological diagnosis that can timely and effectively detect and identify Mycoplasma pneumoniae resistance genes to facilitate precise treatment.
[0008] Summary of the Invention
[0009] In view of this, in a first aspect, the present invention provides a composition for detecting Mycoplasma pneumoniae resistance genes, comprising:
[0010] First nucleic acid composition:
[0011] 23S_rRNA upstream and downstream primers as shown in SEQ ID NO: 1-2;
[0012] 16S_rRNA upstream and downstream primers as shown in SEQ ID NO: 3-4;
[0013] Upstream and downstream primers for detecting gyrA_285 as shown in SEQ ID NOs: 5-6; and
[0014] Upstream and downstream primers for detecting parC_259 as shown in SEQ ID NO: 7-8; and
[0015] Second nucleic acid composition:
[0016] Detection 16S_964R single base extension primer as shown in SEQ ID NO:9;
[0017] Detection 16S_1169F single base extension primer as shown in SEQ ID NO: 10;
[0018] Detection 16S_1173R single base extension primer as shown in SEQ ID NO: 11;
[0019] Detection 23S_2063F single base extension primer as shown in SEQ ID NO: 12;
[0020] Detection 23S_2064R single base extension primer as shown in SEQ ID NO: 13;
[0021] Detection 23S_2067R single base extension primer as shown in SEQ ID NO: 14;
[0022] a gyrAR detection single-base extension primer as shown in SEQ ID NO: 15; and
[0023] The detection parC R single base extension primer is shown as SEQ ID NO:16.
[0024] Furthermore, the first nucleic acid composition is subjected to a multiplex PCR reaction, and the second nucleic acid composition is subjected to a single base extension reaction.
[0025] This method utilizes multiplex PCR and nucleic acid mass spectrometry to simultaneously detect drug-resistant sites on the 23S rRNA, 16S rRNA, gyrA, and parC genes of Mycoplasma pneumoniae in a single reaction tube. For each sample, only a single nucleic acid extraction and single-tube PCR amplification are required, resulting in a low sample volume, high sensitivity and accuracy, and a low limit of detection. This allows for the detection of multiplexed detection in a single reaction tube, even with a large number of samples.
[0026] Furthermore, the composition includes upstream and downstream primers for detecting the internal standard.
[0027] In some specific embodiments, the internal standard is a human internal standard gene. In a specific embodiment, the internal standard is a human housekeeping gene.
[0028] Furthermore, in some embodiments, the compositions of the present invention may include one or more pairs of the aforementioned upstream and downstream primers and single-base extension primers, but subsequent single-base extension primers must be compatible with the previous multiplex amplification upstream and downstream primers. In the present invention, a "pair" refers to mutually matching upstream and downstream primers for detecting a target and any number of single-base extension primers corresponding to the target, such as three, two, or even one single-base extension primer corresponding to the target.
[0029] In some embodiments, the compositions of the present invention can be combined into combinations corresponding to eight targets. Those skilled in the art can determine the desired combinations based on the targets to be detected, by combining upstream and downstream primer pairs and single-base extension primers corresponding to the targets. These combinations are encompassed by the present invention.
[0030] For example, any 4 of the 4 pairs of primers, any 3 of the 4 pairs of primers, any 2 of the 4 pairs of primers, or any 1 of the 4 pairs of primers.
[0031] In some specific embodiments, the compositions of the present invention can be used for PCR.
[0032] In a specific embodiment, the components of the first nucleic acid composition of the present invention are present in one package; and the components of the second nucleic acid composition are present in another package.
[0033] Furthermore, the components of the package of the present invention are present in a mixed form.
[0034] In a second aspect, the present invention provides a use of the above-mentioned composition of the present invention in preparing a kit for detecting drug-resistant genes of Mycoplasma pneumoniae, wherein the drug-resistant genes are one or more of 23S rRNA, 16S rRNA, gyrA and parC genes.
[0035] In a third aspect, the present invention provides a kit for detecting drug-resistant genes of Mycoplasma pneumoniae, wherein the kit comprises the composition of the present invention as described above.
[0036] Furthermore, the kit also includes a negative quality control product and a positive quality control product.
[0037] In a specific embodiment, the negative control is at least one of DEPC H2O, physiological saline, and an internal standard gene. The positive control is at least one of a plasmid fragment or a DNA fragment of 23S rRNA, 16S rRNA, gyrA, and parC genes.
[0038] Furthermore, the kit also includes dNTP, PCR buffer and Mg 2+ At least one of .
[0039] Furthermore, the kit further comprises: at least one of a nucleic acid releasing reagent, a nucleic acid extracting reagent, a DNA polymerase, a SAP enzyme, and a single-base extension reaction enzyme.
[0040] Furthermore, the kit further comprises a nucleic acid releasing reagent, a nucleic acid extracting reagent, dNTP, DNA polymerase, SAP enzyme, single base extension reaction enzyme, PCR buffer, SAP buffer, single base extension buffer, and Mg 2+ At least one of .
[0041] Furthermore, the concentration of the DNA polymerase is 3 U / reaction to 15 U / reaction. For example, the DNA polymerase may be Taq enzyme.
[0042] In a specific embodiment, the kit of the present invention comprises: Taq enzyme, SAP enzyme, single base extension enzyme, Mg 2+ , dNTPs, primers, PCR buffer, SAP buffer, single base extension buffer.
[0043] In some embodiments, the PCR buffer includes Tris-HCl, MgCl2, KCl, Triton X-100.
[0044] In some embodiments, the total volume of the reaction solution in a single PCR reaction tube is 9-18 μl.
[0045] In a fourth aspect, a use of a composition for preparing a reagent for detecting Mycoplasma pneumoniae resistance genes is provided, wherein the detection comprises the following steps:
[0046] 1) Extracting or releasing nucleic acid from the sample to be tested;
[0047] 2) performing PCR amplification on the nucleic acid obtained in step 1) using the composition of the present invention or the kit of the present invention as described above;
[0048] 3) performing a SAP reaction on the product obtained in step 2);
[0049] 4) performing a single base extension reaction on the product obtained in step 3);
[0050] 5) Obtain and analyze the results.
[0051] In the present invention, the sample used for detection can be alveolar lavage fluid, sputum, etc., but is not limited thereto.
[0052] Furthermore, the reaction conditions of the PCR are:
[0053] UNG enzyme activation, temperature at 30℃ for 10 minutes, 1 cycle; pre-denaturation, temperature at 95℃ for 120 seconds, 1 cycle; denaturation, temperature at 95℃ for 30 seconds, annealing, temperature at 63℃ for 30 seconds, extension, temperature at 72℃ for 1 minute, 45 cycles, and finally continued extension at 72℃ for 5 minutes, one cycle.
[0054] Furthermore, the SAP reaction conditions are: 37° C. for 40 minutes and 85° C. for 5 minutes.
[0055] Furthermore, the single base extension reaction conditions are: 95°C for 30 seconds, (95°C for 5 seconds, (52°C for 5 seconds, 80°C for 5 seconds) for 5 cycles) for 40 cycles, and 72°C for 3 minutes.
[0056] In a specific embodiment, a method for detecting Mycoplasma pneumoniae drug resistance genes is provided, the method comprising the following steps:
[0057] 1) Extracting or releasing nucleic acid from the sample to be tested;
[0058] 2) performing PCR amplification on the nucleic acid obtained in step 1) using the composition of the present invention or the kit of the present invention;
[0059] 3) performing a SAP reaction on the product obtained in step 2);
[0060] 4) performing a single base extension reaction on the product obtained in step 3);
[0061] 5) Obtain and analyze the results.
[0062] Furthermore, the reaction conditions of the PCR are:
[0063] UNG enzyme activation, temperature at 30℃ for 10 min, 1 cycle; pre-denaturation, temperature at 95℃ for 120 seconds, 1 cycle; denaturation, temperature at 95℃ for 30 seconds, annealing, temperature at 63℃ for 30 seconds, extension, temperature at 72℃ for 1 minute, 45 cycles, and finally continued extension at 72℃ for 5 minutes, one cycle.
[0064] Furthermore, the SAP reaction conditions are: 37° C. for 40 minutes and 85° C. for 5 minutes.
[0065] Furthermore, the single base extension reaction conditions are: 95°C for 30s, (95°C for 5s, (52°C for 5s, 80°C for 5s) for 5 cycles) for 40 cycles, and 72°C for 3 minutes.
[0066] In a specific embodiment, the method of the present invention for detecting drug-resistant genes of Mycoplasma pneumoniae is a detection method for non-diagnostic purposes. BRIEF DESCRIPTION OF THE DRAWINGS
[0067] FIG1 is a graph showing the detection results of eight drug-resistant sites using the composition of the present invention. During detection, a lower primer peak indicates that the primer is consumed, and the corresponding bases are simultaneously generated and corresponding peaks are generated on the graph;
[0068] Figures 2 to 9 are local magnified peak graphs of eight targets;
[0069] FIG10 is a graph showing the detection results of eight drug-resistant sites detected by the comparative example composition of the present invention. DETAILED DESCRIPTION
[0070] The present invention will be described in detail below in conjunction with specific embodiments and examples, and the advantages and various effects of the present invention will be more clearly presented. It should be understood by those skilled in the art that these specific embodiments and examples are for illustrating the present invention, rather than for limiting the present invention.
[0071] Example 1: Primers used in the present invention
[0072] The primers used in the present invention are shown in Table 1.
[0073] Table 1
[0074] Example 2: Method for detecting drug-resistant genes of Mycoplasma pneumoniae
[0075] Sample processing and loading
[0076] Take 200 μL of the sample to be tested, negative control, and positive control into a 1.5 mL centrifuge tube and use the nucleic acid extraction or purification reagent of Shengxiang Biotechnology Co., Ltd. according to its instructions to extract nucleic acid.
[0077] 6.5 μL of the extracted nucleic acid, negative control, and positive control were added to the corresponding 0.2 mL PCR reaction tubes.
[0078] PCR amplification
[0079] Prepare the multiplex PCR reaction solution according to Table 2. Add 3.5 μl of the reaction solution to each 0.2 mL PCR reaction tube and perform amplification according to the configuration in Table 3.
[0080] Table 2
[0081] Table 3
[0082] SAP response
[0083] Prepare the SAP reaction solution according to Table 4, add 4 μl of the reaction solution to each 0.2 mL PCR reaction tube, and perform the SAP reaction at 37°C for 40 min, 85°C for 5 min, and 4°C for ∞.
[0084] Table 4
[0085] Single base extension reaction
[0086] Prepare the single-base extension reaction solution according to Table 5. Add 4 μl of the reaction solution to each 0.2 mL PCR reaction tube and perform the single-base extension reaction at 95°C for 30 seconds, (95°C for 5 seconds, (52°C for 5 seconds, 80°C for 5 seconds)*5)*40, 72°C for 3 minutes, and 4°C for ∞.
[0087] Table 5
[0088] Interpretation of test results
[0089] Based on the multiplex amplification results, the nucleic acid mass spectrometer displays corresponding single-base extension products for each of the eight drug-resistant genes, with corresponding peaks appearing on the results display to determine if the corresponding drug resistance has been detected. The results accurately detect all eight drug resistances, with target fragment weights separated by at least 16 daltons. The signal is not oversaturated, and the signals between targets are relatively even, with no broad or double peaks.
[0090] Example 3: Test results of test samples of the composition of the present invention
[0091] The method of the present invention includes two cycling steps: a multiplex amplification step and a single-base extension step. After the multiplex amplification step amplifies the MP resistance-associated gene fragment, the single-base extension step extends the amplified fragment one base further using a designed primer. In the present invention, a nucleic acid mass spectrometer is used to detect drug resistance-associated sites. The presence of a corresponding resistance site is indicated by the presence of a peak at the corresponding base.
[0092] The primers described in Example 1 were used to detect and differentiate samples according to the method of Example 2. The test results are shown in Figure 1, while Figures 2 to 9 provide detailed illustrations of each peak. As can be seen from the figures, all eight drug-resistant loci were detected, with clear peaks and no broad or double peaks, demonstrating that the composition of the present invention can detect and differentiate eight drug-resistant genes in a single tube.
[0093] Example 4: Verification of the accuracy, sensitivity and specificity of the composition of the present invention
[0094] Results for the experimental sites were obtained using a gradient dilution of a sequence-specific plasmid. Peaks at all sites were clear, with virtually no gray areas, minimizing the likelihood of false positives. The accuracy, sensitivity, and specificity of each site were verified (see Table 6), leading to a detection limit of 200 copies / ml.
[0095] Table 6
[0096] Comparative Example 1: Other primers designed by the present invention that have poor effects
[0097] Due to the principle of complementary base pairing, primers can form dimers, but this probability is very low and can be eliminated at the beginning of the design. However, when testing for multiple pathogens, there are many primers, and primers are prone to dimers. To ensure conservative design (conservatism is crucial to test accuracy) and to consider mutual interference between different primers, careful primer design is required.
[0098] Therefore, the inventors also designed some other primers (sequences not shown) to form different detection systems, which were also used for the eight drug-resistant sites of Mycoplasma pneumoniae. The specific test results are shown in Figure 10. The results show that this detection system only shows corresponding peaks at the 23S rRNA 2063 site, the 23S rRNA 2064 site, and the gyr A 285 site, among which the Par C259 site shows a clear double peak, and the test results are inaccurate. These primers are unable to fully detect the eight drug resistances, and therefore the overall detection effect is poor.
Claims
1. A composition for detecting drug-resistant genes of Mycoplasma pneumoniae, comprising: First nucleic acid composition: Detection of 23S_rRNA upstream and downstream primers as shown in SEQ ID NO: 1-2; 16S_rRNA upstream and downstream primers as shown in SEQ ID NO:3-4; Upstream and downstream primers for detecting gyrA_285 as shown in SEQ ID NOs: 5-6; and Upstream and downstream primers for detecting parC_259 as shown in SEQ ID NO:7-8; and Second nucleic acid composition: Detection 16S_964R single base extension primer as shown in SEQ ID NO:9; Detection 16S_1169F single base extension primer as shown in SEQ ID NO: 10; Detection 16S_1173R single base extension primer as shown in SEQ ID NO:11; Detection 23S_2063F single base extension primer as shown in SEQ ID NO:12; Detection 23S_2064R single base extension primer as shown in SEQ ID NO:13; Detection 23S_2067R single base extension primer as shown in SEQ ID NO:14; a detection gyrA R single base extension primer as shown in SEQ ID NO: 15; and The detection parC R single base extension primer is shown as SEQ ID NO:
16.
2. The composition according to claim 1, wherein The first nucleic acid composition is subjected to a multiplex PCR reaction, and the second nucleic acid composition is subjected to a single base extension reaction.
3. The composition according to any one of claims 1 to 2, wherein The composition includes upstream and downstream primers for detecting an internal standard.
4. The composition according to any one of claims 1 to 3, wherein The components of the first nucleic acid composition are present in one package; the components of the second nucleic acid composition are present in another package.
5. The composition according to claim 4, wherein The components of the package are present in mixed form.
6. Use of the composition according to any one of claims 1 to 5 in preparing a kit for detecting drug-resistant genes of Mycoplasma pneumoniae, wherein The drug resistance gene is one or more of 23S rRNA, 16S rRNA, gyrA and parC genes.
7. A kit for detecting drug-resistant genes of Mycoplasma pneumoniae, the kit comprising the composition according to any one of claims 1 to 5.
8. The kit according to claim 7, wherein The kit also includes a negative quality control product and a positive quality control product.
9. The kit according to claim 7 or 8, wherein The kit also includes a nucleic acid release reagent, a nucleic acid extraction reagent, dNTPs, a DNA polymerase, a SAP enzyme, a single base extension reaction enzyme, a PCR buffer, a SAP buffer, a single base extension buffer, and Mg 2+ At least one of .
10. A method for detecting Mycoplasma pneumoniae resistance genes, the method comprising the following steps: 1) Extracting or releasing nucleic acid from the sample to be tested; 2) performing multiplex PCR on the nucleic acid obtained in step 1) using the composition according to any one of claims 1 to 5 or the kit according to any one of claims 7 to 9; 3) performing a SAP reaction on the product obtained in step 2); 4) performing a single base extension reaction on the product obtained in step 3); 5) Obtain and analyze the results.
Citation Information
Patent Citations
Method for detecting resistant mutant of mycoplasma pneumoniae
CN102002522A
Specific primer pair for detecting drug resistance mutation gene of mycoplasma pneumoniae and detection kit
CN106566874A
Mycoplasma pneumoniae rapid detection primer group and kit
CN109735640A
Kit and detection method for detecting mycoplasma pneumoniae nucleic acid and drug resistance gene variation of mycoplasma pneumoniae nucleic acid
CN113462794A
Composition and kit for detecting drug-resistant gene of mycoplasma pneumoniae and application of composition and kit
CN116516037A
